Glaukos Corporation (NYSE: GKOS) recently received a number of ratings updates from brokerages and research firms:

  • 9/20/2017 – Glaukos Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 9/18/2017 – Glaukos Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/15/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $38.00 price target on the stock.
  • 9/15/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at Stephens. They now have a $47.00 price target on the stock.
  • 9/14/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock, up previously from $54.00. They wrote, “Numbers out of the Way. Yes, 2Q17 revenue growth was impacted several factors: implementation of updated rates and commercial private payers (20% of the market) and sampling by a competitor. Yes, unfortunately these headwinds will remain in place for the rest of the year, coupled with the impact of the hurricanes (TX and FL represents 7% of overall sales). Accordingly, we have lowered our 2017 revenue estimate from $167 million to $158 million. If nothing else happened today, we would perhaps understand the outsized negative reaction (stock is down ~20% intraday).””
  • 9/14/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 9/12/2017 – Glaukos Corporation was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/1/2017 – Glaukos Corporation was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/1/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $54.00 price target on the stock.
  • 8/26/2017 – Glaukos Corporation was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/16/2017 – Glaukos Corporation was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/7/2017 – Glaukos Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 8/5/2017 – Glaukos Corporation was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Glaukos Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $41.00 price target on the stock. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 8/3/2017 – Glaukos Corporation had its price target lowered by analysts at Roth Capital from $60.00 to $54.00. They now have a “buy” rating on the stock.
  • 8/3/2017 – Glaukos Corporation had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $56.00 price target on the stock.

Glaukos Corporation (NYSE:GKOS) opened at 31.27 on Tuesday. The company’s 50 day moving average is $36.29 and its 200-day moving average is $36.29. The firm’s market cap is $1.08 billion. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.

In other Glaukos Corporation news, CEO Thomas William Burns sold 73,788 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $37.93, for a total transaction of $12,327,250.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 980,200 shares of company stock valued at $37,900,263. Insiders own 16.40% of the company’s stock.

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.